Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 2, 1996, Pages 913-920

  Szczepanik, Ann Marie ^a   Brougham, Linda R ^a   Roehr, Joachim E ^a   Conway, Paul G ^a   Ellis, Daniel B ^a   Wilmot, Carole A ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBENZYLHYDRAZINE; APOMORPHINE; AUTORECEPTOR; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GAMMA BUTYROLACTONE; HALOPERIDOL; ILOPERIDONE; KETANSERIN; METHYSERGIDE; NEUROLEPTIC AGENT; PRAZOSIN; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SPIPERONE; SULPIRIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG RECEPTOR BINDING; FRONTAL CORTEX; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; AUTORADIOGRAPHY; BRAIN; DIHYDROXYPHENYLALANINE; DOPAMINE ANTAGONISTS; ISOXAZOLES; MALE; PIPERIDINES; RATS; RATS, WISTAR; SEROTONIN ANTAGONISTS;

EID: 0030426914     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. 3H]spiroperidol. J. Pharmacol. Exp. Ther. 233: 527-538, 1985.
2. 2 receptors: An autoradiographic analysis in rat brain. Brain Res. Bull. 16: 517-525, 1986.
3. 2 receptors in rat cerebral cortex. J. Neurochem. 46: 191-197, 1986.
4. BALDESSARINI, R. J. AND FRANKENBURG, F. R.: Drug therapy: Clozapine. N. Engl. J. Med. 324: 746-754, 1991.
5. BALDESSARINI, R. J. AND TARSEY, D.: Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia. Int. Rev. Neurbiol. 21: 1-44, 1979.
6. BALSARA, J. J., JADHAV, J. H. AND CHANDORKAR, A. G.: Effects of drugs influencing central serotonergic mechanisms on haloperodol-induced catalepsy. Psychopharmacology 62: 67-69, 1979.
7. 2 receptor blocking agent. Curr. Ther. Res. 40: 492-499, 1986.
8. BLEICH, A., LYNN-BROWN, S., KOHN, R. AND VAN PRAAG, H. M.: The role of serotonin in schizophrenia. Schizophr. Bull. 14: 297-315, 1988.
9. BORISON, R. L. AND DIAMOND, B. I.: Regional selectivity of neuroleptic drugs: An argument for site specificity. Brain Res. Bull. 11: 215-218, 1983.
10. BORISON, R. L., FIELDS, J. Z. AND DIAMOND B. I.: Site specific blockade of dopamine receptors by neuroleptic agents in human brain. Neuropharmacology 20: 1321-1322, 1981.
11. BORISON, R. L., HITRI, A., BLOWERS, A. J. AND DIAMOND, B. I.: Antipsychotic drug action: Clinical, biochemical, and pharmacological evidence for site specificity of action. Clin. Neuropharmacol. 6: 137-150, 1983.
12. 2 dopamine and muscarinic cholinergic receptors in rat striatum. J. Pharmacol. Exp. Ther. 244: 987-992, 1988.
13. CARLSSON, J., KEHR, W., LINDQVIST, M., MAGNUSSON, T. AND ATACK, C. V.: Regulation of monoamine metabolism in the central nervous system. Pharmacol. Rev. 24: 371-384, 1972.
14. 2 antagonist risperidone (R 64 766) in the treatment of chronic psychosis. Schizophr. Res. 2: 411-415, 1989.
15. CLARK, D. AND WHITE, F. J.: Review: D1 dopamine receptor - The search for a function: A critical evaluation of D1/D2 dopamine receptor classification and it's functional implications. Synapse 1: 347-388, 1987.
16. CORBETT, R., HARTMAN, H., KERMAN, L. L., WOODS, A. T., STRUPCZEWSKI, J. T., HELSLEY, G. C., CONWAY, P. G. AND DUNN, R. W.: Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol. Biochem. Behav. 45: 9-17, 1993.
17. COSTALL, B., FORTUNE, D. H., NAYLOR, R. J., MARSDEN, C. D. AND PYCOCK, C.: Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 14: 859-868, 1975.
18. COWARD, D. M.: General pharmacology of clozapine. Br. J. Psychiatry (Suppl.) 17: 5-11, 1992.
19. CREESE, I., BURT, D. R. AND SNYDER, S. H.: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science (Wash. DC) 192: 481-183, 1976.
20. ERESHEFSKY, L. AND LACOMBE, S.: Pharmacological profile of risperidone. Can. J. Psychiatry 38: Suppl. 3, S80-S88, 1993.
21. HERRLING, P. L.: Mechanism of action of atypical antipsychotics. Clin. Neuropharmacol. 13: Suppl. 2, 265-266, 1990.
22. HOYBERG, O. J., REMVIG, F. C., LINGJAERDE, O., SLOTH-NIELSEN, M. AND SALVESEN, I.: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatry Scand. 88: 395-402, 1993.
23. JANSSEN, P. A. J., NIEMEGEERS, C. J. E., AIVEUTERS, F., SCHELLEKENS, K. H. L., MEGENS, A. A. H. P. AND MEERT, T. F.: Pharmacology of risperidone (R64766), a new antipsychotic with serotonergic-S2 and dopamine D2 antagonistic properties. J. Pharmacol. Exp. Ther. 244: 685-693, 1988.
24. KANE, J. M., HONIGFELD, G., SINGER, J., MELTZER, H. AND THE CLOZARIL COLLABORATIVE STUDY GROUP.: Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 45: 789-796, 1988.
25. KAHN, R. S. AND DAVIS, K. L: New developments in dopamine and schizophrenia. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 1193-1203, Raven Press, New York, 1995.
26. LAI, H., CARINO, M. A. AND HORITA, A.: Antiserotonin properties of neuroleptic drugs. In Psychopharmacology and Biochemistry of Neurotransmitter Receptors, ed. H. I. Yamamura, R. W. Olsen and E. Usdin, pp. 347-353, Elsevier Scientific, Amsterdam, 1980.
27. 2) receptor numbers in the rat brain. Psychiatry Res. 12: 277-285, 1984.
28. LOSONCZY, M. F., DAVIDSON, M. AND DAVIS, K. L.: The dopamine hypothesis of schizophrenia. In Psychopharmacology: The Third Generation of Progress, ed. by H. Y. Meltzer, pp. 715-726, Raven Press, New York, 1987.
29. MAJ, J., SARNEK, J., KLIMEK, V. AND RAWLOW, A.: On the anticataleptic action of cyroheptadine. Pharmacol. Biochem. Behav. 5: 210-205, 1976.
30. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J. Pharmacol. Exp. Ther. 265: 498-508, 1993.
31. MELTZER, H. Y.: Relevance of dopamine autoreceptors for psychiatry: Preclinical and clinical studies. Schizophr. Bull. 6: 456-475, 1980.
32. MELTZER, H. Y.: The importance of serotonin-dopamine interactions in the action of clozapine. Br. J. Psychiatry 160: Suppl. 17, 22-29, 1992.
33. 2 pKi values. J. Pharmacol. Exp. Ther. 251: 238-246, 1989.
34. MELTZER, H. Y. AND STAHL, S. M.: The dopamine hypothesis of schizophrenia: A review. Schizophr. Bull. 2: 19-76, 1976.
35. MELTZER, H. Y., YOUNG, M., METZ, J., FANG, V. S., SCHYVE, P. M. AND AURORA, R. C.: Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J. Neural Trans. 45: 165-175, 1979.
36. MESOTTEN, F., SUY, E., PIETQUIN, M., BURTON, P., HEYLEN, S. AND GELDERS, Y.: Therapeutic effect and safety of increasing doses of risperidone (R64766) in psychotic patients. Psychopharmacol. (Berl.) 99: 445-449, 1989.
37. MIN, S. K., RHEE, C. S., KIM, C. E. AND KANG, D. Y.: Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: A parallel group double-blind comparative trial. Yonsei Med. J. 34: 179-190, 1993.
38. 3H)spiperone. Life Sci. 34: 2507-2514, 1984.
39. MULLER, P. AND SEEMAN, P.: Dopaminergic supersensitivity after neuroleptics: Time course and specificity. Psychopharmacology 60: 1-11, 1978.
40. O'DELL, S. J., LA HOSTE, G. J., WIDMARK, C. B., SHAPIRO, R. M., PUTKIN, S. G. AND MARSHALL, J. F.: Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6: 146-153, 1990.
41. PAXINOS, G. AND WATSON, C.: The Rat Brain Atlas in Stereotaxic Coordinates, Academic Press, New York, 1982.
42. PEROUTKA, S. J. AND SNYDER, S. H.: Relationship of neuroleptic drag effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiatry 137: 1518-1522, 1980.
43. ROTH, R. H. AND ELSWORTH, J. D.: Dopamine autoreceptor signal transduction and regulation. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 227-243, Raven Press, New York, 1995.
44. ROTH, B. L AND MELTZER, H. Y.: The role of serotonin in schizophrenia. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 1215-1227, Raven Press, New York, 1995.
45. RUPNIAK, N. M. J., HALL, M. D., MANN, S., FLEMINGER, S., KILPATRICK, G., JENNER, P. AND MARSDEN, C. D.: Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem. Pharmacol. 34: 2755-2763, 1985.
46. 2 antagonists modulate the effects of D-2 dopamine receptor blockade. J Pharmacol. Exp. Ther. 253: 1162-1170, 1990.
47. SCHOTTE, A., JANSSEN, P. F. M., MEGENS, A. A. H. P. AND LEYSEN, J. E.: Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 631: 191-202, 1993.
48. SEEMAN, P.: Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1: 133-152, 1987.
49. SEEMAN, P. AND ULPIAN, C.: Neuroleptics have identical potencies in human brain limbic and putamen regions. Eur. J. Pharmacol. 94: 145-148, 1983.
50. 2 antagonists with potential atypical antipsychotic activity: Antipsychotic profile of iloperidone (HP873). J. Med. Chem. 38: 1119-1131, 1995.
51. SZEWCZAK, M. R., CORBETT, R., RUSH, D. K., WILMOT, C. A., CONWAY, P. G., STRUPCZEWSKI, J. T. AND CORNFELDT, M.: The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J. Pharmacol. Exp. Ther., 274: 1404-1413, 1995.
52. TALLARIDA, R. J. AND MURRAY, R. B.: Manual of Pharmacologic Calculations with Computer Programs, Springer-Verlag, New York, 1987.
53. WALTERS, J. R. AND ROTH, R. H.: Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 274: 5-14, 1976.
54. WESTERINK, B. H. C.: The effects of drugs on dopamine biosynthesis and metabolism. In Neurobiology of Dopamine, ed. by A. S. Horn, J. Korf and B. H. S. Westerink, pp. 251-290, Academic Press, London, 1979.
55. 2 receptors in the rat brain. Brain Res. 487: 288-298, 1989.